drugset
Drugs / AZD1305
last change Jun 2011 re-read 9 days ago

AZD1305

Small molecule targets KCNH2, SCN5A via inhibition

Developed for
atrial fibrillation · atrial flutter · left ventricular failure
Investigated by
AstraZeneca

Trials 13

today NCT00957437 · Ph 1 NCT00935025 · Ph 1 NCT00915356 · Ph 2 NCT00748982 · Ph 2 NCT00712465 · Ph 1 NCT00738322 · Ph 1 NCT00707551 · Ph 1 NCT00689247 · Ph 1 NCT00643448 · Ph 2 NCT00689403 · Ph 1 NCT00616629 · Ph 2 NCT00688831 · Ph 1 NCT00689039 · Ph 1
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 19 trials
Phase 1 NCT00957437 Aug → Nov 2009 — AstraZeneca Completed No outcome recorded
Phase 1 NCT00935025 Jul → Nov 2009 — AstraZeneca Terminated No outcome recorded
Phase 1 NCT00712465 Aug → Nov 2008 atrial fibrillation AstraZeneca Completed No outcome recorded
Phase 1 NCT00738322 Jul → Oct 2008 — AstraZeneca Completed No outcome recorded
Phase 1 NCT00707551 Jul → Nov 2008 — AstraZeneca Completed No outcome recorded
Phase 1 NCT00689247 Apr → May 2008 — AstraZeneca Completed No outcome recorded
Phase 1 NCT00689403 Feb → Jul 2008 — AstraZeneca Completed No outcome recorded
Phase 1 NCT00688831 Jan → May 2008 — AstraZeneca Completed No outcome recorded
Phase 1 NCT00689039 Apr 2007 → Jul 2008 — AstraZeneca Completed No outcome recorded
Phase 24 trials · 1 met primary
Phase 2 NCT00915356 May → Dec 2009 atrial fibrillation AstraZeneca Completed Met primary
Phase 2 NCT00748982 Aug 2008 → Jul 2009 left ventricular failure AstraZeneca Completed No outcome recorded
Phase 2 NCT00643448 Mar → Aug 2008 atrial fibrillation AstraZeneca Completed No outcome recorded
Phase 2 NCT00616629 Jan → Jun 2008 atrial flutter AstraZeneca Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 15 sources stand behind the page.

FieldValueCited text
Known as AZD1305 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00688831 ↗
12

NCT00616629 ↗

NCT00712465 ↗

NCT00689247 ↗

NCT00935025 ↗

NCT00915356 ↗

NCT00748982 ↗

NCT00738322 ↗

NCT00707551 ↗

NCT00957437 ↗

NCT00689403 ↗

Show 2 more sources
Action Inhibit “Sodium channel protein type V alpha subunit blocker” CHEMBL3545169 ↗
2

“combined potassium and sodium channel inhibition” PMID 21619383 ↗ Jun 2011

“HERG blocker” CHEMBL3545169 ↗
Modality Small molecule — CHEMBL3545169 ↗
Route Intravenous “Intravenous infusion” NCT00616629 ↗
Target KCNH2 “HERG blocker” CHEMBL3545169 ↗
Target SCN5A “Sodium channel protein type V alpha subunit blocker” CHEMBL3545169 ↗